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A B S T R A C T
Background: The Xience VTM everolimus-eluting stent is a new generation drug-eluting stent (DES) that 
incorporates a low profile cobalt-chromium platform (81 μm) and a highly biocompatible polymer 
(fluoropolymer), which carries and controls the release of everolimus. Recent studies have demonstrated 
sustained safety and efficacy of the Xience VTM in the treatment of real-world populations. Our aim was to 
report the clinical results of 12 months of the BRAVO Brazilian protocol.
Methods: The BRAVO Registry was a prospective, non-randomized, single-arm, multicenter (25 centers) 
study that evaluated the late clinical results of 535 minimally selected patients treated with the drug- 
eluting stent Xience VTM in Brazilian daily practice.
Results: Overall, 40% of patients had diabetes, 25% prior myocardial infarction, and 42% presented with 
acute coronary artery syndrome. The majority of lesions (69%) was highly complex (ACC/AHA type B2 or 
C). The mean length and the nominal stent diameter were 19.9 ± 5.3 mm and 3.0 ± 0.4 mm, respectively. 
The angiographic and procedural successes were 99.7 and 98%, respectively. At 12 months, the cumulative 
rate of major adverse cardiac events, available in 100% of patients, was 5.6% (cardiac death: 1.3%; acute 
myocardial infarction: 3.0%; revascularization of the target lesion: 2.2%). Stent thrombosis occurred in 5 
patients (0,9%), and only 1 case was reported between 6 and 12 months.
Conclusions: The drug-eluting stent Xience VTM demonstrated sustained safety and efficacy up to 12 
months in the treatment of complex coronary lesions in patients from daily practice.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Seguimento de 12 meses de pacientes complexos tratados com stents 
farmacológicos liberadores de everolimus XIENCE V® na prática diária – 
resultados do registro brasileiro BRAVO
R E S U M O
Introdução: O stent liberador de everolimus XIENCE V® é um stent farmacológico de nova geração 
que incorpora uma plataforma de cromo-cobalto de baixo perfil (81 m) e um polímero de elevada 
biocompatibilidade (fluoropolímero), o qual carreia e controla a liberação do fármaco everolimus. Estudos 
recentes demonstram segurança e eficácia sustentadas do dispositivo XIENCE V® no tratamento de 
populações da prática clínica. Nosso objetivo foi reportar resultados clínicos de 12 meses do protocolo 
brasileiro BRAVO.
Métodos: O registro BRAVO foi um estudo prospectivo, não randomizado, de braço único, multicêntrico (25 
centros), que avaliou os resultados clínicos tardios de 535 pacientes minimamente selecionados, tratados 
com o stent farmacológico XIENCE V®.
Resultados: Cerca de 40% dos pacientes tinham diabetes, 25% infarto agudo do miocárdio prévio e 42% 
apresentaram-se com síndrome coronária aguda. A maioria das lesões (69%) era de elevada complexidade 
(ACC/AHA tipo B2/C). As médias da extensão e do diâmetro nominais dos stents foram, respectivamente, 
19,9 ± 5,3 mm e 3,0 ± 0,4 mm. Os sucessos angiográfico e de procedimento foram de 99,7% e 98%, 
respectivamente. Aos 12 meses, a taxa cumulativa de eventos cardíacos adversos maiores, disponível em 
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Introduction
In general, the new generation of drug-eluting stents (DES) has 
shown high efficacy and safety in the treatment of patients with 
coronary lesions in daily practice.1-3 Compared with older DES,4,5 
these devices are characterized by the presence of smaller profile 
metallic components, drug carrier systems with optimized biocom-
patibility and potent antiproliferative agents.6-13
The XIENCE VTM stent (Abbott Vascular, Santa Clara, USA) incor-
porates an 81 m thick cobalt-chromium platform with a non-
thrombogenic polymer (fluoropolymer), which carries and controls 
the everolimus release.6 Recent studies with the XIENCE VTM stent, 
including real-world populations, have shown low occurrence of 
major adverse cardiac events (MACE) and late and very late stent 
thrombosis.14-19
Specifically in the 6 month follow-up of BRAVO registry (BRazil 
XIENCE VTM Everolimus-Eluting Coronary Stent System “Real-World” 
Outcomes Registry), which evaluated 535 patients, the cumulative 
rates of MACE (4.3%), cardiac death (1.1%) and stent thrombosis 
(0.8%) were relatively low, especially considering a complex Brazil-
ian cohort treated at multiple centers in daily practice.20 However, 
long-term follow-up data are still needed to better assess the impact 
of this device in our population. Thus, our objective was to report 
the clinical results of the 12 month follow-up of patients included in 
the BRAVO protocol.
Methods
Protocol and procedure
The protocol details and the initial results of the BRAVO registry 
had been previously reported.20 In short, this was a prospective, 
non-randomized, single-arm, multicenter (25 centers), national, 
post-marketing clinical trial, which used a validated electronic data 
capture system, independently managed by a Representative Orga-
nization of Clinical Research in São Paulo (SP). The objective of the 
study was to assess the late clinical outcomes in minimally selected 
patients (exclusion: saphenous graft and life expectancy < 24 
months) undergoing percutaneous coronary intervention (PCI) with 
XIENCE VTM DES in Brazilian daily practice. Patients with at least one 
lesion with stenosis ≥ 50%, located in a native coronary artery with 
favorable anatomy for PCI with stenting were included. In general, 
PCI procedures were performed according to current guidelines,21 
and the final strategy was left to the operator’s discretion. The avail-
able stents had the following measurements: 2.5, 3.0 and 3.5 mm in 
diameter, and 8, 12, 15, 18, 23 and 28 mm in length. In relation to 
dual antiplatelet therapy (DAPT) recommendations after the proce-
dure, aspirin was prescribed indefinitely and thienopyridine (clopi-
dogrel) was prescribed for at least 12 months.
Clinical outcomes and definitions
The primary study outcome was the occurrence of MACE in the 
12 months of follow-up. The considered late clinical outcomes in-
cluded target-lesion revascularization (TLR) at 6 and 12 months, 
stent thrombosis and major bleeding up to 12 months. The composite 
MACE outcome was defined as cardiac death, acute myocardial in-
farction (AMI) and TLR. Target-vessel revascularization (TVR) in-
cluded cases of TLR.
Stent thrombosis was defined according to the criteria of the 
Academic Research Consortium (ARC).22 Major bleeding followed 
the Thrombolysis in Myocardial Infarction (TIMI) criteria, includ-
ing intracranial hemorrhage or absolute decrease ≥ 5 g/dL in hemo-
globin concentrations or absolute decrease ≥ 15% in hematocrit 
levels.23
Clinical follow-up was scheduled at 30 days, 6, 12 and 24 months 
post-procedure and consisted of medical consultations or telephone 
contact carried out according to a predefined protocol. A total of 535 
patients were enrolled between September 2008 and September 
2010, and all (100%) completed the follow-up at 12 months.
All adverse events had their information directly verified in the 
source documentation and were later adjudicated by an indepen-
dent Clinical Events Committee, which included three experienced 
professionals from the Clinical and Invasive Cardiology areas. For 
the current analysis, clinical results were reported up to 12 months.
Statistical analysis
Categorical variables are shown as frequencies and percentages. 
Quantitative variables are shown as mean and standard deviation.
Results
Baseline and procedure characteristics
The baseline clinical and angiographic characteristics are shown 
in Table 1. Overall, 40% of patients had diabetes, 25% had a previous 
AMI, and 42% had acute coronary syndrome (ACS), including 29% 
with unstable angina, 9% with AMI without ST-segment elevation, 
and 4% with AMI with ST-segment elevation. Regarding the PCI pro-
cedure, 14% received multiple stents, 42% had post-dilation with bal-
loon catheter and the mean nominal length and nominal diameter of 
the stents were, respectively, 19.9 ± 5.3 mm and 3.0 ± 0.4 mm. At the 
end of the procedure, the angiographic and procedure success were 
99.7% and 98%, respectively.
Clinical events
Table 2 shows the cumulative rates of adverse events up to 12 
months of clinical follow-up. Between 6 and 12 months, there were 
seven new cases of MACE, including two cardiac deaths. In the first 
case, a 53 year-old patient with multiple risk factors (systemic arte-
rial hypertension – SAH, diabetes, dyslipidemia, smoking, acute 
myocardial infarction and previous coronary artery bypass graft – 
CABG), had initially two lesions treated in the right coronary artery 
in the presence of ACS, but developed inferior AMI with ST-segment 
elevation followed by death 245 days after the procedure. In the sec-
ond case, a 70 year-old female, with a history of SAH, dyslipidemia 
100% dos pacientes, foi de 5,6% (morte cardíaca: 1,3%; infarto agudo do miocárdio: 3,0%; revascularização 
da lesão-alvo: 2,2%). Já a trombose de stent ocorreu em cinco pacientes (0,9%), sendo reportada apenas uma 
ocorrência entre 6 e 12 meses.
Conclusões: O stent farmacológico XIENCE V® demonstrou segurança e eficácia sustentadas ao final de 12 
meses no tratamento de lesões coronárias complexas em pacientes da prática diária.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and diabetes, had the left anterior descending artery treated in the 
index procedure due to the clinical picture of stable angina func-
tional class III; however, she showed recurrence of the lesion in the 
treated vessel and progression of atherosclerotic disease, being sub-
mitted to CABG; she developed postoperative complications and 
died on the day 289. Additionally, three patients had non-cardiac 
death due to the development of pancreatic cancer (day 246), multi-
ple trauma (day 280) and respiratory failure (day 295).
The cumulative rate of any stent thrombosis reported up to 12 
months was 0.9%, totaling five cases; the rate of definitive/probable 
stent thrombosis was 0.6% (three cases). The detailed description of 
the cases is shown in Table 3. Finally, cases of major bleeding accord-
ing to the TIMI criteria were reported in three patients up to 12 
months of follow-up and, in one case, the patient had two distinct 
episodes of gastrointestinal bleeding (Table 4).
Discussion
In general, the clinical results at 12 months in the current analy-
sis, which involved a relatively large number of minimally selected 
patients (n = 535) obtained from the national daily practice, con-
firmed the safety and efficacy profile previously observed in our 
registry at 6 months.20 They were also comparable to a series of re-
ported studies with the XIENCE VTM device in real-world popula-
tions, which showed high rates of procedure success (96% to 99%), as 
well as clinical safety and effectiveness that persisted during the 
late and very late follow-up (Table 5).14-19 These findings unequivo-
cally suggest a very favorable performance of this second-genera-
tion everolimus-eluting DES in different clinical settings, including 
high-risk subgroups.
In the BRAVO registry, the MACE rate at 6 months was 4.3%20; 
however, there were seven new occurrences of this outcome be-
tween 6 and 12 months, representing a small increase (approximate-
ly 1.3%) during the period. It is noteworthy the fact that the new 
revascularization, due to the late stenosis recurrence or disease pro-
gression, was the main determining factor in six of seven new re-
ported cases. In the era of balloon angioplasty, the main late 
recurrence mechanism seemed to be vascular remodeling or recoil, 
with the binary angiographic restenosis occurring in up to 50% of 
the cases. Regarding the cases of post-bare metal stent recurrence, 
they have been associated mainly with neointimal hyperplasia, with 
rates ranging between 20% and 30%.4,5,24,25
It was noteworthy that, in both situations, the incidence peak 
seemed to occur at the similar time, between 3 and 6 months.26 
However, with the DES, the formation of neointimal tissue is signifi-
cantly inhibited – binary angiographic restenosis usually < 10% and 
such process is also delayed due to the local action of the antiprolif-
erative drug.1,4-12,27 Therefore, albeit unlikely, cases of recurrence 
may occur at a later stage (> 6 months) in comparison with bare-
metal stents (≤ 6 months). However, the predictors classically associ-
Table 1
Baseline clinical and angiographic characteristics.
Variable n = 535 
(770 lesions)
Age, years 62.7 ± 11.1
Female gender, n (%) 171 (32.0)
Diabetes mellitus, n (%) 214 (40.0)
Using insulin 60 (11.2)
Hypertension, n (%) 433 (80.9)
Dyslipidemia, n (%) 407 (76.1)
Smoking history, n (%) 234 (43.7)
Current smoking 101 (18.9)
Family history of CAD, n (%) 265 (49.5)
Previous myocardial infarction n (%) 133 (24.9)
Previous PCI, n (%) 206 (38.5)
Previous CABG, n (%) 54 (10.1)
Previous stroke, n (%) 21 (3.9)
CHF functional class III or IVa, n (%) 39 (7.3)
Renal failureb, n (%) 33 (6.2)
Peripheral vascular disease, n (%) 25 (4.7)
Clinical presentation of ACS, n (%) 224 (41.9)
Target vessel, n (%)
Left anterior descending artery 335 (46.1)
Left circumflex artery 181 (23.5)
Right coronary artery 213 (27.7)
Left main coronary artery 21 (2.7)
Bifurcation, n (%) 89 (11.6)
Total occlusion, n (%) 48 (6.2)
In-stent restenosis, n (%) 54 (7.0)
Type B2/C lesionc, n (%) 531 (69.0)
Lesion length, mm 17.8 ± 7.3d
Reference vessel diameter, mm 3.0 ± 1.4d
Stenosis diameter, % 82.9 ± 10.1d
CAD: coronary artery disease; PCI: percutaneous coronary intervention; CABG: coronary artery by-
pass graft; CHF: congestive heart failure; ACS: acute coronary syndrome.
a According to the New York Heart Association classification.
b Defined by the measurement of baseline serum creatinine ≥ 1.5 mg/dL.
c According to the modified classification of the American College of Cardiology/American Heart 
Association.
d Estimated by visual analysis, as reported by the operator.
Table 2
Cumulative rates of adverse events up to 12 months of follow-up (n = 535).
Event Hospital 30 days 6 months 12 months
MACE, n (%) 10 (1.9) 13 (2.4) 23 (4.3) 30 (5.6)
Cardiac death, n (%) 0 (0) 2 (0.4) 5 (0.9) 7 (1.3)
MI, n (%) 10 (1.9) 10 (1.9) 12 (2.2) 16 (3.0)
TLR, n (%) 0 (0) 1 (0.2) 5 (0.9) 12 (2.2)
TVR, n (%) 0 (0) 2 (0.4) 7 (1.3) 15 (2.8)
ST, n (%) 1 (0.2) 2 (0.4) 4 (0.8) 5 (0.9)
Definitive 1 0 0 1
Probable 0 1 0 0
Possible 0 0 2 0
MACE: major adverse cardiac events; MI: myocardial infarction; TLR: target lesion revascularization; 
TVR: target vessel revascularization; ST: stent thrombosis.
Table 3
Description of stent thrombosis cases reported up to 12 months of follow-up (organized by the time up to the event from the index procedure).
Case Age 
(years)
Gender Previous history Indication Target vessel Event presentation Use of DAPT Days until 
the event
Adjudication (ARC 
criterion)22
1 52 M SAH, dyslipidemia, smoking, 
PVD, previous MI, previous PCI
ACS LAD/Dg 
(bifurcation)
Unstable angina Yes 0 Definite ST (acute)
2 75 F DM, SAH, dyslipidemia Silent ischemia Dg (1st branch) Sudden death Yes 28 Probable ST 
(subacute)
3 80 M SAH, dyslipidemia, smoking, 
CHF, permanent pacemaker
UA class II RCA Sudden death Yes 42 Possible ST (late)
4 77 M DM, SAH, dyslipidemia, 
dialytic CRF
ACS LAD (2 lesions) Sudden death Yes 154 Possible ST (late)
5 53 F DM, SAH, dyslipidemia, 
smoking, previous MI, 
previous CABG
ACS RCA (2 lesions) AMI with ST 
elevation
Yes 245 Definitive ST (late)
DAPT: dual antiplatelet therapy; ARC: Academic Research Consortium; M: male; SAH: systemic arterial hypertension; PVD: peripheral vascular disease; AMI: acute myocardial infarction; PCI: percutaneous 
coronary intervention; ACS: acute coronary syndrome; LAD: left anterior descending artery; Dg: diagonal branch: ST: stent thrombosis; F: female; DM: diabetes mellitus; CHF: congestive heart failure; SA: 
stable angina; RCA: right coronary artery; CRF: chronic renal failure; CABG: coronary artery bypass graft surgery.
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ated with post-PCI restenosis (diabetes, long lesions, small-caliber 
vessels, complex lesions, etc.) remain the same.28,29
Interestingly, in addition to neointimal hyperplasia, recent stud-
ies have demonstrated a new post-stent recurrence mechanism, in-
cluding the neoatherosclerosis process, which can occur even in the 
presence of second-generation DES.30,31 Serial analyses of quantita-
tive coronary angiography in the SPIRIT II and III studies showed 
relatively low rates of binary angiographic restenosis in the segment 
treated with XIENCE VTM stent (3.4 to 4.7% at 6 and 8 months, respec-
tively), which were associated with TLR rates of 1.8% at 6 months 
(SPIRIT II) and 3.4% at 12 months (SPIRIT III).17,18 Similarly, clinical re-
stenosis rates in the BRAVO registry were 0.9% at 6 months and 2.2% 
at 12 months, despite the high prevalence of diabetes, ACS and com-
plex lesions. These findings demonstrate the clinical effectiveness of 
the second-generation DES, especially of the everolimus-releasing 
system, even in more complex populations (Table 5).
Despite the remarkable efficacy in reducing neointimal hyper-
plasia, restenosis, and thus the need for new revascularization 
demonstrated by the first-generation DES vs. bare-metal stents,4,5 
safety-related concerns, particularly in late and very late stages,3 
eventually prompted the research and development of new DES sys-
tems, aiming at a better safety profile. A series of studies showed, 
quite clearly, the multifactorial profile associated with the genesis of 
thrombosis post-DES implantation.3,32,33 Of note, among others, are 
the characteristics associated with: comorbidities and clinical pre-
sentation (diabetes, renal failure, ACS, etc.); lesion morphology and 
procedure (complex lesions, bifurcation, thrombus, multivessel PCI, 
stent underexpansion, dissection, etc.); DAPT interruption (mainly 
in the first 6 months); and stent type.
Nevertheless, even considering the current evidence, it is not 
completely determined to which extent (or to what degree) one or 
another of these characteristics, or a combination of them, may in-
fluence and/or predict the occurrence of stent thrombosis. Regard-
ing DES, strut thickness, biocompatibility of the carrier systems and 
the action mechanism of the antiproliferative drug have been con-
sidered decisive components for performance and safety profile, 
both early and late/very late. Among the most used second-genera-
tion DES, the thin chrome-cobalt and platinum-cobalt metallic plat-
forms (74-91 microns) are commonly found.6,9,10,13 In relation to the 
carrier systems, they incorporate “non-thrombogenic” or biode-
gradable polymers with a better biocompatibility profile, when 
compared to those durable polymers used in older DES.6-13,34
Finally, drugs from the “limus” family currently prevail.6-13 Three 
randomized trials comparing the XIENCE VTM stent vs. Taxus™ pacli-
taxel-eluting stent (Boston Scientific, Natick, USA) showed lower 
rates of MACE and stent thrombosis with the first one in the 12 
months of follow-up.14,17,18 Three other randomized studies showed 
non-inferiority of everolimus-releasing DES vs. CYPHERTM sirolimus-
releasing stent (Cordis Corp., Warren, USA) regarding the clinical 
outcomes at 12 or 18 months of follow-up;15,16,35 however, very late 
stent thrombosis rate (> 1 year) seems to be lower with the everoli-
mus-releasing system.3
Stent thrombosis rates reported up to 1 year with the XIENCE VTM 
stent ranged from 0.4% to 1.2%. In our population, this rate (definite/
Table 4
Description of major bleeding cases according tothe TIMI17 criterion up to 12 months of follow-up (organized by time up to the event from the index procedure).
Case Age 
(years)
Gender History Indication Target Vessel Event presentation Use of DAPT Days until the 
event
Treatment/ Evolution
1 75 M DM, SAH, dyslipidemia, CRF ACS RCA, LCx Gastrointestinal 
bleedinga
Yes 12 Packed red blood cell 
transfusion
Gastrointestinal 
bleedinga,b
Yes 75 Packed red blood cell 
transfusion
2 70 M SAH, dyslipidemia, smoking, 
CHF, definitive pacemaker, 
gastrointestinal bleeding
SA class II RCA Rectal bleeding Yes 20 Death (non-cardiac)
3 87 M SAH, dyslipidemia ACS LMCA, LAD, LCx Hemorrhagic stroke Yes 153 Death (non-cardiac)
DAPT: dual antiplatelet therapy; M: male; DM: diabetes mellitus; SAH: Systemic arterial hypertension; CRF: chronic renal failure; ACS: acute coronary syndrome; RCA: right coronary artery; LCx: left circum-
flex artery; CHF: congestive heart failure; SA: stable angina; LMCA: left main coronary artery; LAD: left anterior descending artery.
a Event associated with the decrease in serum hemoglobin levels ≥ 5 g/dL.
b Second bleeding event in the same patient (case 1).
Table 5
Comparison of clinical studies with XIENCE VTM Everolimus-eluting stent.
Study BRAVO COMPARE14 RESET15 EXCELLENT16 SPIRIT III17 SPIRIT IV18 TWENTE19
Patients, n 535 897 1,597 1,079 669 2,458 694
Lesions, n 770 1,286 1,967 1,459 772 3,142 1,036
Diabetics, % 40 17 45 37 30 32 21
ACS, % 42 60 18 53 19 28 51
LAD, % 46 40 49 50 41 41 42
Bifurcation, % 12 17 39 11 ND ND 25
B2/C lesion, % 69 74 ND 53 ND ND 70
Lesion length, mm 17.8 16.8 17.0 20.31 14.7 14.8 14.30
RVD, mm 3.0 2.56 2.58 2.87 2.77 2.75 2.66
Procedure success, % 98 98 97.8 99 NA NA 95.8
Follow-up at 12 months, % 100 100 98 98.9 97.9 98.3 99.7
MACE, % 5.6 5 6.2 3.8 6 4.2 9
Cardiac death, % 1.3 1 1 0.3 0.8 0.4 1.4
MI, % 3 3 3 1.4 2.8 1.9 4.6
TLR, % 2.2 2 4.3 2.4 3.4 2.5 1.4
TVR, % 2.8 2 6.9 3.1 6.1 3.9 NA
ST (definitive/probable), % 0.6 0.7 0.4 0.4 1.1 0.3 1.2
ACS: acute coronary syndrome; LAD: left anterior descending artery; NA: not available; RVD: reference vessel diameter; MACE: major adverse cardiac events; MI: myocardial infarction; TLR: target lesion 
revascularization; TVR: target vessel revascularization; ST: stent thrombosis.
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probable) was 0.6%, despite the high prevalence of diabetic patients 
(40%), ACS (42%) and complex lesions (69% B2/C type). Considering 
only the late (between 1 and 12 months) stent thrombosis  (definite/
probable), the rate was extremely low (0.2%), representing only one 
occurrence.
It is noteworthy the fact that most patients that had any stent 
thrombosis (n = 5) had multiple clinical comorbidities and ACS in the 
index procedure, although they were being treated with DAPT at the 
time of the thrombotic event. Nonetheless, the evaluation of event 
incidence in the very late clinical follow-up (not yet reported) is re-
quired, so the sustainability of these results can be verified.
Conclusions
Results of the late clinical follow-up of the BRAVO Brazilian mul-
ticenter registry showed sustained safety and efficacy of the XIENCE 
VTM everolimus-eluting stent in the treatment of complex coronary 
lesions in minimally selected patients from the national daily prac-
tice, including relatively low stent thrombosis (< 1%) and target-le-
sion revascularization rates (2.2%) after 12 months.
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